一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模大、学术水平高、具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国胃食管与肝胆胰肿瘤领域Poster Session共入选38项。期待中国专家在ASCO年会上展现风采！
胃肠道肿瘤-胃食管与肝胆胰
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
01
摘要号：4029
标题：A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or me[x]tastatic esophageal squamous cell carcinoma.
报告人：黄镜
单位：中国医学科学院肿瘤医院
02
摘要号：4031
标题：A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer: 2-Year update data.
报告人：季加孚
单位：北京大学肿瘤医院
03
摘要号：4034
标题：EpCAM CAR T (IMC001) for the treatment of advanced GI cancers.
报告人：Guoqiang Ai
单位：Suzhou Immunofoco Biotechnology Co., Ltd
04
摘要号：4037
标题：Effect of autologous lymphocytes combined with chemotherapy as the first-line treatment of advanced gastric cancer.
报告人：Xiaoting Ma
单位：中国医学科学院肿瘤医院
05
摘要号：4041
标题：Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase Ⅱ clinical trial.
报告人：Zhiye Zhang
单位：河南科技大学第一附属医院
06
摘要号：4046
标题：Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002).
报告人：沈琳
单位：北京大学肿瘤医院
07
摘要号：4047
标题：Heterogeneous ba[x]seline immune cell infiltration landscape as a predictor of pathological complete response in locally advanced esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemotherapy and immunotherapy: Results from a single-arm, phase II clinical trial (SEEK-01).
报告人：Guangyu Yao
单位：复旦大学附属中山医院
08
摘要号：4048
标题：Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial.
报告人：弓磊
单位：天津医科大学肿瘤医院
09
摘要号：4049
标题：Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).
报告人：鲁智豪
单位：北京大学肿瘤医院
10
摘要号：4054
标题：Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.
报告人：俞鹏飞
单位：浙江省肿瘤医院
11
摘要号：4056
标题：Predicting role of circulating tumor DNA and blood-ba[x]sed tumor mutational burden in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with toripalimab: Exploratory analyses from a phase II trial (EC-CRT-001).
报告人：陈宝清
单位：中山大学肿瘤防治中心
12
摘要号：4058
标题：Concordance among the three commercially available PD-L1 assays for esophageal squamous cell carcinoma.
报告人：Lizhen Wang
单位：罗氏(中国)投资有限公司
13
摘要号：4060
标题：Multi-dimensional cell-free DNA-ba[x]sed liquid biopsy and early detection of gastric cancer.
报告人：俞鹏飞
单位：浙江省肿瘤医院
14
摘要号：4061
标题：Induction chemotherapy plus definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: Long-term results and exploratory analyses of a randomized controlled trial.
报告人：习勉
单位：中山大学肿瘤防治中心
15
摘要号：4064
标题：Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study.
报告人：张仁泉
单位：安徽医科大学第一附属医院
16
摘要号：4068
标题：Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study.
报告人：Peng Jin
单位：山东省肿瘤医院
18
摘要号：4069
标题：GaEsSeer: Early detection of gastric and esophageal cancer by integrating methylation and fragmentomics signatures in cfDNA.
报告人：钟芸诗
单位：复旦大学附属中山医院
19
摘要号：4071
标题：Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated biliary tract cancer.
报告人：何文卓
单位：中山大学肿瘤防治中心
20
摘要号：4072
标题：Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.
报告人：张志波
单位：福建医科大学附属第一医院
21
摘要号：4077
标题：An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.
报告人：毕锋
单位：四川大学华西医院
22
摘要号：4079
标题：Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.
